ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;88:849-855. doi:10.1016/j.athoracsur.2009.06.003
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Eric J. Devaney
Edward L. Bove
Jennifer C. Hirsch
Richard G. Ohye
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Konuma, T.
Right arrow Articles by Ohye, R. G.
PubMed
Right arrow Articles by Konuma, T.
Right arrow Articles by Ohye, R. G.
Related Collections
Right arrow Congenital - cyanotic

Original Articles: Pediatric Cardiac

Performance of CryoValve SG Decellularized Pulmonary Allografts Compared With Standard Cryopreserved Allografts

Takeshi Konuma, MD, Eric J. Devaney, MD, Edward L. Bove, MD, Sarah Gelehrter, MD, Jennifer C. Hirsch, MD, Zarry Tavakkol, MD, Richard G. Ohye, MD*

Divisions of Pediatric Cardiovascular Surgery and Pediatric Cardiology, University of Michigan Medical School, Ann Arbor, Michigan

Accepted for publication June 1, 2009.

* Address correspondence to Dr Ohye, 5144 CVC/SPC 5864, 1500 East Medical Center Dr, Ann Arbor, MI 48109 (Email: ohye{at}umich.edu).

Presented at the Fifty-fifth Annual Meeting of the Southern Thoracic Surgical Association, Austin, TX, Nov 5–8, 2008.

Background: There is no ideal option for pulmonary valve replacement in children. Cryopreserved pulmonary allografts frequently demonstrate early valve regurgitation and may elicit an immune response. To improve these shortcomings, the SynerGraft process (CryoLife, Kennesaw, GA) decellularizes an allograft, leaving only connective tissue, which then becomes repopulated with host cells. A previous study at our institution demonstrated superior short-term durability of the SynerGraft-processed CryoValve SG compared with standard allografts. Longer-term impact of the technology remains unknown.

Methods: A single institution review was performed of all CryoValve SGs implanted between 2001 and 2004. Forty-one CryoValve SG patients and 41 age and diagnosis-matched standard allograft controls were evaluated. Demographics, survival, reintervention, and echocardiographic findings were analyzed.

Results: There were no significant differences between groups in demographics, valve diameter, orthotopic-heterotopic allograft position, or follow-up. For the entire cohort, there was no difference in early or late insufficiency or stenosis at a mean follow-up of 46 ± 14 months. However, freedom from moderate to severe insufficiency (>3+) was significantly better for CryoValve SG patients (p = 0.05). In addition, for patients greater than 2 years of age, CryoValve SGs were significantly less regurgitant (p = 0.045) and stenotic (p = 0.041). Long-term survival was identical at 85% (35 of 41).

Conclusions: When compared with standard allografts, CryoValve SGs demonstrate superior freedom from significant insufficiency at intermediate follow-up. In older children, CryoValve SGs display less insufficiency and stenosis. For infants, patient age, valve diameter, previous conduit, and rapid somatic growth would likely be the predominant factors leading to allograft failure.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.